Zobrazeno 1 - 6
of 6
pro vyhledávání: '"J. Ignacio Chacón"'
Autor:
Isabel Álvarez, Angel Guerrero-Zotano, Ariadna Tibau, Catalina Falo, María Hernández, Ana Miguel, Raquel Andrés, Álvaro Rodríguez-Lescure, Miguel Corbellas, Sara López-Tarruella, Purificación Martínez, Cesar A Rodríguez, Diego Malón, María Marin, Mª José Echarri, Antonio Antón, Josefina Cruz, Diana Moreno, J. Ignacio Chacón, Ruth Campo, Andrea Blasco, Susana Bezares, Federico Rojo, Silvia Antolin
Publikováno v:
Cancer Research. 83:P4-07
Background: HER2-low breast cancer (BC) is a new therapeutic entity, but it is uncertain if this subgroup of BC differs from HER2-negative tumors in clinical characteristics, prognosis, and response to therapy. The objective is to describe the clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24a0bce9786ce02386dbba6e66063c87
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-30
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-30
Autor:
Sara López-Tarruella, Angel Guerrero-Zotano, Josefina Cruz, Silvia Antolin Novoa, Purificación Martínez, María Hernández, César A Rodríguez, J. Ignacio Chacón, Ariadna Tibau, Catalina Falo, Álvaro Rodríguez-Lescure, Mireia Margelí, Sonia Servitja, Raquel Andrés, María Galán-Gramaje, Encarna Adrover, Ana Miguel, Rafael Villanueva, Silvia Varela, Ruth Campo, Mª José Escudero, Susana Bezares, Federico Rojo, Isabel Álvarez
Publikováno v:
Cancer Research. 83:P4-07
Background: Over the last years, the treatment of HER2-positive (HER2+) breast cancer (BC) patients (pts) has been changing because of the development of new anti-HER2 agents. In the current analysis, we describe the features, treatment patterns, pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::899553d6b964d08519e6b9057c90c5e3
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-38
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-38
Autor:
Sara López-Tarruella, Ángel Guerrero-Zotano, César A Rodríguez, Josefina Cruz, María Hernández, Encarna Adrover, Álvaro Rodríguez-Lescure, Catalina Falo, Purificación Martínez, Ana Miguel, Raquel Andrés, Silvia Antolín, J. Ignacio Chacón, Jose Luis Alonso Romero, Rafael Villanueva Vázquez, Ana Isabel Ballesteros García, María Galán Gramaje, Diego Malón Jiménez, Silvia Varela Ferreiro, Diana Moreno Muñoz, Ruth Campo, María José Escudero, Susana Bezares, Federico Rojo, Isabel Alvarez
Publikováno v:
Cancer Research. 82:PD4-08
Background: The incidence of breast cancer brain metastases (BCBM) is estimated to be around 5-15%, but necropsies show a much higher incidence (30-50%). Frecuency of BCBM has gradually increase likely as a result from advances in systemic treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::181e953c29e325267a524eef3e68bc59
https://doi.org/10.1158/1538-7445.sabcs21-pd4-08
https://doi.org/10.1158/1538-7445.sabcs21-pd4-08
Autor:
Noelia Martínez-Jáñez, Meritxell Bellet Ezquerra, Fernando Henao, Luis Manso, Antonio Antón, Pilar Zamora, Serafin Morales Murillo, Pablo Tolosa, Raquel Andrés, Lourdes Calvo, Elena Galve, Rafael Lopez, Francisco Ayala de la Peña, Sara López-Tarruella, Laia Boronat, Tamara Martos, J. Ignacio Chacón, Isabel Álvarez, Juan de la Haba-Rodríguez, Fernando Moreno Antón
Publikováno v:
Cancer Research. 83:P4-01
INTRODUCTION AND OBJECTIVES Palbociclib associated with hormone therapy (HT) has shown significant benefit in progression-free survival (PFS) and response rate versus HT alone in patients with HR+, HER2- MBC. The PALBOSPAIN study evaluates the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f87747767f6aa9ba086d791bb61d4a12
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-28
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-28
Autor:
W. Fraser Symmans, Miguel Martin, Frankie A. Holmes, Meredith Buxton, Joyce O'Shaughnessy, Christos Hatzis, Vicente Valero, Yun Wu, Tatiana Vidaurre, Arlene Nazario, Yun Gong, Henry L. Gomez, Richard Dyer, Angela DeMichele, Lajos Pusztai, Wei Yang, Hongkun Wang, Jose M. Cotrina, Ana Lluch, Laura J. Esserman, Daniel J. Booser, Eduardo A. Souchon, Gabriel N. Hortobagyi, Rebekah Hubbard, Jaime Ferrer-Lozano, J. Ignacio Chacón, Naoto T. Ueno, Nuhad K. Ibrahim, Eleni Andreopoulou, Kelly K. Hunt
Publikováno v:
JAMA. 305:1873
Prediction of high probability of survival from standard cancer treatments is fundamental for individualized cancer treatment strategies.To develop a predictor of response and survival from chemotherapy for newly diagnosed invasive breast cancer.Pros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b7343a422ff620bdf5f88e338bad3c5
https://doi.org/10.1001/jama.2011.593
https://doi.org/10.1001/jama.2011.593
Publikováno v:
Middle East Journal of Cancer. Jan2022, Vol. 13 Issue 1, p1-13. 13p.